Immunotherapy combo shows promise in early lung cancer trial
NCT ID NCT02621398
First seen Jan 07, 2026 · Last updated Jun 19, 2026 · Updated 32 times
Summary
This early-phase trial tested the safety and best dose of adding the immunotherapy drug pembrolizumab (Keytruda) to standard chemotherapy (paclitaxel and carboplatin) and radiation therapy for people with stage II to IIIB non-small cell lung cancer. The study enrolled 23 participants and focused on finding the maximum tolerated dose and any serious side effects, especially lung inflammation. While the combination aims to boost the immune system's ability to kill cancer cells, it is still too early to know if it improves long-term outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE IIIA NON-SMALL CELL LUNG CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey, 08903, United States
-
University of Pennsylvania/Abramson Cancer Center
Philadelphia, Pennsylvania, 19104, United States
-
Yale Cancer Center
New Haven, Connecticut, 06510, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
pembrolizumab (Keytruda) plus paclitaxel, carboplatin, and radiation therapy
What this could lead to
If it works, this could point toward a more effective treatment for locally advanced non-small cell lung cancer by combining immunotherapy with standard chemo and radiation.
What could go wrong
This is a very early phase 1 trial with only 23 participants, so the main goal is safety, not effectiveness. The combination may cause severe side effects like lung inflammation, and it's too soon to know if it improves survival.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.